Source: PainChek Limited
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • PainChek has secured a distribution agreement with Person Centred Software to release its facial recognition tool in the United Kingdom
  • This newe product will help more than 850,000 dementia suffers in the UK
  • Data analytics are used to determine the source and severity of pain by analysing the patients face

PainChek Limited has secured a binding distribution agreement with Person Centred Software to expand its PainChek tool to the UK market.

This agreement will allow PainChek’s tool to be distributed to Person’s strong customer base of more than 1,200 aged care providers and 40,000 residents.

It will be distributed through its sale, marketing and service capabilities, in the hopes to provide carers with a quick and easy transition into pain assessment.

Person Centred Software is designed to give carers more time to spend with their clients. Everything is recorded electronically with a few taps on a device so less paperwork needs to be completed and less time is spent away from the patients.

“We are delighted to be working with Person Centred Software. Their team and product offering is highly complimentary to PainChek and together we can leverage the positive learnings and market acceptance from Australia into an even larger market. The agreement will provide us with rapid access to their large UK client base,” CEO, PainChek, Phillip Daffas said.

The application uses the smartphone camera to record a short video of the patients face and then analyses the images using facial recognition. The facial muscle movements that indicate pain are automatically recognised and taken note of.

Carers then record their observations of the pain related to past behaviours such as how the person is moving and vocalising pain. PainChek will then calculate an overall pain score and stores the result allowing the carer to monitor the medication and treatments over time.

While for now it is primarily used for dementia sufferers who can’t speak it is believed PainChek is looking for ways to adapt it to children who have not yet learned how to speak.

PainChek has been granted clearance for the European Union where there is an estimated 7.5 million people living with dementia, 850,000 in the UK, and more than 20 million carers.

The board of PainChek has discussed to setting up operations in the UK in the near future, believing it to be an extremely beneficial opportunity.

“We are establishing a core PainChek UK team who can take advantage of the large European market opportunity and work with strategic partners, like Person Centred Software, on a country by country basis,” Phillip said.

This announcement sent PainChek’s shares rise 32.9 percent to currently sit at 12 cents per share.

PCK by the numbers
More From The Market Online

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…

AVITA Medical drops revenue forecast for Q1

AVITA Medical (ASX:AVH) provided an update on its anticipated revenue for Q1 2024 - and has…

Little Green Pharma heading into Q2 cashed up after record sales

Little Green Pharma (ASX:LGP) wound up Q1CY24 with $5M in cash after posting record sales of…

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch…